1. Combining Sitagliptin with Metformin enhances glucose control more effectively than either drug alone, reducing both fasting and postprandial glucose levels.

2. Sitagliptin and Metformin, when used together, improve glycemic control by acting via complementary mechanisms, thus targeting different aspects of type 2 diabetes.

3. The combination of Sitagliptin and Metformin reduces the risk of hypoglycemia compared to sulfonylurea-based therapies and offers a favorable weight profile.

4. This dual therapy helps in managing type 2 diabetes by increasing insulin release and decreasing sugar production in the liver, providing a comprehensive treatment approach.